GRI Bio, Inc.

NasdaqCM:GRI

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 3.10 M

Share Price

USD 1.32

Avg Daily Volume

497,880

Change (1 day)

-5.71%

Change (1 year)

Change (YTD)

-85.62%

GRI Bio, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -85.62%

GRI Bio, Inc. Share Price Year-To-Date (YTD) return is -85.62% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

GRI Bio, Inc. 52-week low Share Price is USD 9.43 on June 20, 2025, which is 614.39% above the current Share Price.
GRI Bio, Inc. 52-week low Share Price is USD 1.20 on June 20, 2025, which is -9.09% below the current Share Price.
GRI Bio, Inc. average Share Price for the last 52 weeks is USD 3.37.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqCM: GRI

GRI Bio, Inc.

CEO	Dr. W. Marc Hertz Ph.D.
IPO Date	Feb. 10, 2021
Location	United States
Headquarters	2223 Avenida de la Playa
Employees	3
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.